Introduction
============

Gastrointestinal stromal tumours (GISTs) are the most common type of soft tissue sarcomas that arise from the mesenchymal cells of the gastrointestinal tract and have characteristic histological and molecular features ([@b1-ijo-56-06-1468]). According to the literature, most GISTs are driven by activating mutations in the proto-oncogenes *KIT* and *PDGFRA* ([@b2-ijo-56-06-1468]). In total, \~85% of malignant GISTs harbour activating mutations in one of the genes, *KIT* or *PDGFRA*, while 10-15% of all GISTs have no detectable *KIT* or *PDGFRA* mutations ([@b2-ijo-56-06-1468]-[@b4-ijo-56-06-1468]).

Receptors KIT and platelet derived growth factor receptor α (PDGFRA) have a similar structure and activation mechanism, as they belong to the same sub-family, the type III receptor tyrosine kinases ([@b5-ijo-56-06-1468]). Their typical structure is composed of an extracellular (EC) domain, a transmembrane domain, an intracellular juxtamembrane (JM) domain and a cytoplasmic kinase domain, which is divided by a kinase insert into two catalytic parts, tyrosine kinase domain I (TK I) and tyrosine kinase domain II (TK II) ([@b6-ijo-56-06-1468]).

Gain-of-function mutations in *KIT* or *PDGFRA* gene cause functional changes in KIT or PDGFRA receptor, which lead to constitutive, ligand-independent phosphorylation of the receptor and activation of downstream to KIT/PDGFRA signalling pathways (RAS/RAF/MAPK, PI3K/AKT/mTOR and JAK/STAT3), ultimately increasing cell proliferation and inhibiting apoptosis ([@b6-ijo-56-06-1468],[@b7-ijo-56-06-1468]).

In GIST, 67% of *KIT* mutations occur in exon 11 (JM domain). The mutation frequency in other regions of the KIT receptor is markedly lower; mutations in exon 9 (EC domain) occur in 8-10% of GISTs, whilst exons 13 and 17 (TK I and TK II) are mutated in \~1% of all GISTs ([@b8-ijo-56-06-1468]-[@b10-ijo-56-06-1468]). *PDGFRA* mutations occur in \~8% of GISTs, of which exon 14 (TK I) and exon 18 (TK II) are mutated in 6-7% of the GISTs, and exon 12 (JM domain) in 1% ([@b11-ijo-56-06-1468],[@b12-ijo-56-06-1468]).

GISTs without a mutation in the *KIT* or *PDGFRA* genes are historically known as wild-type (WT) GIST; however, their molecular biology is very heterogeneous. *KIT/PDGFRA* WT GISTs can have alterations in genes of the succinate dehydrogenase complex or in *BRAF, PIK3CA*, or rarely *RAS* family genes ([@b13-ijo-56-06-1468],[@b14-ijo-56-06-1468]). *BRAF* V600E mutation has been reported in 7-15% of *KIT/PDGFRA* WT GISTs, meanwhile RAS and PIK3CA mutant GISTs are reported to be very rare ([@b15-ijo-56-06-1468]-[@b18-ijo-56-06-1468]). Even more rare are recently reported NTRK fusions in these patients, however they are important for treatment decisions ([@b19-ijo-56-06-1468]).

Before the discovery of tyrosine kinase inhibitor (TKI) imatinib, no effective therapy was available for the treatment of unresectable, metastatic or recurrent GIST. The overall survival (OS) time of such patients was 9-20 months ([@b20-ijo-56-06-1468],[@b21-ijo-56-06-1468]). With imatinib, the median OS time of patients with advanced GISTs is significantly longer and is reported to be \~55-57 months ([@b21-ijo-56-06-1468]). Although the majority of *KIT/PDGFRA*-mutant GIST patients (90%) achieve clinical benefit from imatinib, primary resistance frequently occurs in GISTs that are *KIT/PDGFRA* WT, have KIT exon 9 mutation or have a substitution D842V in gene *PDGFRA* ([@b22-ijo-56-06-1468],[@b23-ijo-56-06-1468]). Furthermore, secondary resistance develops in 40-50% of patients with GIST within 2 years of successful treatment due to secondary *KIT/PDGFRA* mutations or activating mutations of another downstream signalling pathway, such as the RAS/RAF/MAPK or PI3K/AKT/mTOR path-ways ([@b18-ijo-56-06-1468],[@b22-ijo-56-06-1468],[@b23-ijo-56-06-1468]). Imatinib efficacy greatly depends on tumour genotype; therefore, molecular characterization of GIST is a very important step in optimizing GIST clinical treatment ([@b21-ijo-56-06-1468],[@b23-ijo-56-06-1468]).

The aim of the present study was to molecularly characterize a cohort of 70 patients with metastatic GISTs from the Slovenian Cancer Registry (National Cancer Registry) treated between period 2002 and 2011. The spectrum of *KIT* and *PDGFRA* mutations was reported, as well as the spectrum of hot spot mutations in *KRAS, NRAS, BRAF, PIK3CA* and *AKT1* genes in patients with GIST.

Materials and methods
=====================

Patients
--------

In total, 70 patients with metastatic KIT-positive GIST, treated with TKIs at the Institute of Oncology Ljubljana (Ljubljana, Slovenia) between January 2002 and December 2011, were recruited and included in the present analysis.

Formalin-fixed, paraffin-embedded (FFPE) primary tissue samples were mainly obtained from the Department of Pathology, Institute of Oncology Ljubljana (72%) and also from pathology departments from other hospitals and clinics in Slovenia (University Medical Centre Ljubljana, Ljubljana; University Medical Centre Maribor, Maribor; Izola General Hospital, Izola; and Celje General Hospital, Celje). All patients were treated with TKIs at the Institute of Oncology Ljubljana. In total, 12 of the 70 samples were obtained from patients after the start of imatinib therapy. Clinicopathological characteristics of the patients, as well as prognostic risk groups according to Miettinen *et al* ([@b4-ijo-56-06-1468]), are presented in [Table I](#tI-ijo-56-06-1468){ref-type="table"}.

As controls for immunohistochemistry (IHC), normal appendiceal tissue samples were obtained from 5 patients (3 females, 2 males; age, 57-74 years; median, 63 years) undergoing various surgical procedures. In addition, tumour tissue samples were obtained from 10 patients (6 females, 4 males; age, 42-83 years; meadian, 60 years) with histopathologically confirmed CD117-positive non-metastatic GIST. All patients included as IHC controls were treated at the Institute of Oncology Ljubljana between January 2002 and December 2011.

All collected tumour samples were evaluated and were histopathologically examined under a microscope by pathology specialists, who confirmed the diagnosis using immunohistochemical staining for CD117 antigen expression. IHC analysis of CD117 was performed on 2-4 *µ*m FFPE tissue sections, dried at 56°C for 2 h. Heat-mediated epitope retrieval was performed in a microwave oven using home-brew pH 9.0 Tris-EDTA buffer for 10 min at 100°C at high pressure. Detection was performed in the semi-automated IHC system LabVision™ Autostainer AS480. Endogenous peroxidases were blocked using Dako REAL™ Peroxidase blocking solution (cat. no. S2023; Dako; Agilent Technologies, Inc.) for 8 min at room temperature. CD117 was detected using a commercially available mouse polyclonal antibody CD117 (cat. no. A4502; Dako; Agilent Technologies, Inc.; 1:100), which was added for 30 min at room temperature. The antibody was diluted using Dako REAL™ antibody diluent (cat. no. S2022; Dako; Agilent Technologies, Inc.). Primary antibody was visualised using 2-step polymer detection system Dako REAL™ EnVision™ Detection system, Peroxidase/DAB+ Rabbit/Mouse (cat. no. K5007; Dako; Agilent Technologies, Inc.). Ready to-use secondary antibody Dako REAL™ EnVision™/HRP Rabbit/Mouse (cat. no. K5007; Dako; Agilent Technologies, Inc.) was added for 30 min at room temperature. Chromogene Dako REAL™ DAB+ Chromogen (cat. no. K5007; Dako; Agilent Technologies, Inc.) was diluted at 1:50, according to manufacturer\'s protocol and incubated twice for 7.5 min each at room temperature.

Tissue sections were viewed under a light microscope (magnification, ×10). The section of the FFPE slides that contained the highest number of tumour cells (always \>70% in all GIST samples) was marked and used for DNA extraction.

The present study was approved by the Institutional Review Board of the Institute of Oncology Ljubljana (permission no. OIRIKE00036) and by the National Medical Ethics Committee of Republic of Slovenia (permission no. 1090216). Individual patient consent was waived for this study as it was a retrospective study, the research involved no risk to the subjects, and the institutional informed consent forms for treatment included consent for the use of patient\'s data, materials and/or test results for research purposes. All procedures followed in the present study were therefore in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and the Helsinki Declaration of 1975, as revised in 2013.

Molecular analysis
------------------

Mutational analyses of *KIT, PDGFRA, KRAS, NRAS* and *BRAF* genes were performed by the Department of Molecular Diagnostic at the Institute of Oncology Ljubljana (Ljubljana, Slovenia). Genomic DNA of 70 sporadic GISTs was isolated from FFPE tissues, using macrodissection and standard procedures, according to the manufacturer\'s protocol of the QIAmp DNA FFPE Tissue kit (Qiagen GmbH). The quality and concentration of DNA extracts were assessed using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Inc.).

All GISTs (n=70) were examined for somatic mutations in *KIT* (exons 9, 11, 13 and 17) and *PDGFRA* (exons 12, 14 and 18) by polymerase chain reaction (PCR) amplification and direct Sanger sequencing. For PCR amplification, Invitrogen™EXPRESS SYBR™ GreenER™ qPCR Supermix, universal (Invitrogen; Thermo Fisher Scientific, Inc.), which includes Platinum™ Taq DNA Polymerase, was used. PCR reactions were run on an Applied Biosystems™ 7900HT Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermocycling conditions: Activation at 50°C for 2 min; followed by denaturation at 95°C for 10 min; 20 cycles of denaturation at 95°C for 35 sec, annealing at 64°C for 45 sec and elongation at 72°C for 1 min; followed by another 30 cycles of denaturation at 95°C for 15 sec, annealing at 55°C for 45 sec and elongation at 72°C for 1 min. Direct Sanger sequencing reactions were performed using a Big Dye Terminator v3.1 (Applied Biosystems; Thermo Fisher Scientific, Inc.) and run on an ABI 3500 Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). Specific primers for target exon amplification and sequencing reactions were designed using Primer3 web software (version 0.1g; <http://biotools.nubic.northwestern.edu/Primer3.html>) and are shown in [Table SI](#SD1-ijo-56-06-1468){ref-type="supplementary-material"}.

Furthermore, all patients with *KIT/PDGFRA* WT GIST were tested for the presence of hot spot mutations in *KRAS, NRAS, BRAF, PIK3CA* and *AKT1*. Testing was performed using Colorectal Cancer Mutation Detection Panel v1.3 (EntroGen, Inc.), a quantitative PCR-based assay, according to the manufacturer\'s protocol. A list of all hot spot mutations that are included in the Colorectal Cancer Mutation Detection Panel are presented in [Table SII](#SD1-ijo-56-06-1468){ref-type="supplementary-material"}.

Sequence analysis
-----------------

DNA sequences were analysed using Sequencing Analysis software v5.4 software (Applied Biosystems; Thermo Fisher Scientific, Inc.), ChromasLite software v2.1.1 (Technelysium Pty Ltd.) and GeneRunner software (<http://www.softpedia.com/get/Science-CAD/Gene-Runner.shtml>). Mutation nomenclature followed the recommendations of the Human Genome Variation Society v19.01 (<http://varnomen.hgvs.org/>). Reference sequences used in the present study were taken from the National Centre for Biotechnology Information data-base (<https://www.ncbi.nlm.nih.gov/>): *KIT* (NM_000222.2), *PDGFRA* (NM_006206), *KRAS* (NM_004985), *NRAS* (NM_002524), *BRAF* (NM_004333), *PIK3CA* (NM_006218.2) and *AKT1* (NM_005163.2).

Literature search of detected variants
--------------------------------------

A literature search for all detected variants found in the present study was performed using Alamut Visual v2.11 software (SOPHiA GENETICS). To perform a search for the references of every variant detected, a gene name and a nucleotide change (c.notation) were typed into Alamut Visual browser, which is linked to Google.

Online in silico analysis and bioinformatics tools
--------------------------------------------------

*In silico*mutation prediction analyses were performed using the online bioinformatics tools: Align GVGD (<http://agvgd.hci.utah.edu/>) MutationTaster2 (<http://www.muta-tiontaster.org>), and Cancer Genome Interpreter (<https://www.cancergenomeinterpreter.org/analysis>). Their pathogenicity was assessed according to The American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criterions using Genetic Variant Interpretation Tool (<http://www.medschool.umaryland.edu/Genetic_Variant_Interpretation_Tool1.html/>).

Results
=======

Genotype analysis KIT/PDGFRA mutant GISTs
-----------------------------------------

Among 70 metastatic GIST tumours, 62 (88.6%) *KIT/PDGFRA* mutant GISTs were identified. Of the analysed GISTs, 60 (85.7%) had a mutation in *KIT* and only 2 (2.9%) had a mutation in *PDGFRA*. Of the 60 patients with *KIT* mutant GISTs, 6 (10%) developed a secondary mutation in exon 13 or 17 of the *KIT* gene. These secondary mutations were found in the patients whose tissue samples were obtained following imatinib treatment.

Among the 60 patients with *KIT* mutation, *KIT* exon 11 was mutated in 52 patients (86.7%), harbouring 40 different variants. *KIT* exon 9 was mutated in 6 cases (10%) and all carried a frequent six nucleotides duplication, c.1504_1509dup p.(Ala502\_ Tyr503dup). *KIT* exon 13 was mutated in 5 cases (8.3%); 2 patients had a primary mutation and 3 patients had a secondary mutation. *KIT* exon 17 was mutated in 3 cases (5%), where all 3 patients had a secondary mutation ([Table II](#tII-ijo-56-06-1468){ref-type="table"}).

As aforementioned, mutations in *PDGFRA* were found in 2 cases (2.9%). The first patient had a single nucleotide change in exon 18, c.2525A\>T p.(Asp842Val), while the second patient had two different single nucleotide changes, c.1936A\>G p.(Lys627Glu) and c.1975A\>C p.(Asn659His), both in exon 14. The latter case was a rare example of double mutant GIST ([Fig. 1](#f1-ijo-56-06-1468){ref-type="fig"}). Mutational status and mutation location of all 70 GISTs are presented in [Table II](#tII-ijo-56-06-1468){ref-type="table"}. All detected alterations and their status of pathogenicity in 62 *KIT/PDGFRA* mutant GISTs from the Slovenian Cancer Registry are presented in [Table SIII](#SD1-ijo-56-06-1468){ref-type="supplementary-material"}.

KIT/PDGFRA wild-type GIST
-------------------------

All eight *KIT/PDGFRA* WT GISTs had no mutations in hot spot regions of *KRAS* (codons 12/13/59/61/117/146), *NRAS* (codons 12/13/59/61/117/146), *BRAF* (codon 600), *PIK3CA* (codons 542/545/1047) or *AKT1*(codon 17).

Novel variants
--------------

The present study detected 49 different variants in total, of which eight were novel. A reference search for all detected variants (n=49) was performed using Google browser trough Alamut Visual software, on the 19th of January 2019.

All eight novel heterozygous variants, which had not been reported previously, were detected in exon 11 of gene *KIT*([Figs. 2](#f2-ijo-56-06-1468){ref-type="fig"} and [3](#f3-ijo-56-06-1468){ref-type="fig"}). The precise effect of these eight novel variants on KIT protein function is unknown; however, based on Cancer Genome Interpreter and ACMG/AMP criterions, all of them were classified as likely pathogenic. The classification of all eight novel variants found in *KIT* exon 11 is presented in [Table III](#tIII-ijo-56-06-1468){ref-type="table"} and their descriptions are provided in the following paragraphs.

c.1652_1672del p.(Pro551_Lys558delinsGln) is a deletion of 21 nucleotides in the exon 11 of the *KIT* gene, from position c.1652 to position c.1672. At the protein level, p.(Pro551\_ Lys558delinsGln) results in the deletion of eight amino acids in the JM domain of the KIT protein from amino acids 551 to 558, combined with the insertion of a glutamine (Gln) at the same site ([Fig. 2A](#f2-ijo-56-06-1468){ref-type="fig"}).

c.1653_1660delinsAA p.(Met552_Glu554delinsLys) is a deletion of eight nucleotides in exon 11 of the *KIT* gene, from position c.1653 to position c.1660, and an insertion of two adenine bases at the same position. At the protein level, p.(Met552_Glu554delinsLys) results in the deletion of three amino acids in the JM domain of the KIT protein from amino acids 552 to 554, combined with the insertion of a lysine (Lys) at the same site ([Fig. 2B](#f2-ijo-56-06-1468){ref-type="fig"}).

c.1665_1672delinsCC p.(Trp557_Lys558del) is a deletion of eight nucleotides in exon 11 of the *KIT* gene, from position c.1665 to position c.1672, and an insertion of two cytosine bases at the same position. At the protein level, p.(Trp557\_ Lys558del) results in the deletion of two amino acids in the JM domain of the KIT protein from amino acids 557 to 558 ([Fig. 2C](#f2-ijo-56-06-1468){ref-type="fig"}).

c.1668_1686del p.(Trp557^\*^) is a deletion of 19 nucleotides in exon 11 of the *KIT* gene, from position c.1668 to position c.1686. At the protein level, p.(Trp557^\*^) results in the premature termination of the KIT protein at amino acid 557. Due to the loss of the protein kinase domain, the mutation c.1668_1686del p.(Trp557^\*^) is predicted to lead to a loss of KIT protein function ([Fig. 2D](#f2-ijo-56-06-1468){ref-type="fig"}).

c.1676_1720del p.(Val559_Thr574delinsAla) is a deletion of 45 nucleotides in exon 11 of the *KIT* gene, from position c.1676 to position c.1720. At the protein level, p.(Val559_Thr574delinsAla) results in the deletion of 16 amino acids in the JM domain of the KIT protein from amino acids 559 to 574, combined with the insertion of an Alanine (Ala) at the same site ([Fig. 2E](#f2-ijo-56-06-1468){ref-type="fig"}).

c.1715_1756dup p.(Pro585_Arg586ins14) is a duplication of 42 nucleotides in exon 11 of the *KIT* gene, from position c.1715 to position c.1756. At the protein level, p.(Pro585_Arg586ins14) indicates the insertion of 14 amino acids (Asn, Pro, Thr, Gln, Leu, Pro, Tyr, Asp, His, Lys, Trp, Glu, Phe and Pro) in the JM domain of the KIT protein, starting with Asparagine (Asn) at position 586 ([Fig. 3A](#f3-ijo-56-06-1468){ref-type="fig"}).

c.1721_1765dup p.(Arg588_Leu589ins15) is a duplication of 45 nucleotides in exon 11 of the *KIT* gene, from position c.1721 to position c.1765. At the protein level, p.(Arg588_Leu589ins15) indicates the insertion of 15 amino acids (Pro, Gln, Leu, Pro, Tyr, Asp, His, Lys, Trp, Glu, Phe, Pro, Arg, Asn and Arg) in the JM domain of the KIT protein, starting with Proline (Pro) at position 589 ([Fig. 3B](#f3-ijo-56-06-1468){ref-type="fig"}).

c.1722_1766dup p.(Gln575_Leu589dup) is a duplication of 45 nucleotides in exon 11 of the *KIT* gene, from position c.1722 to position c.1766. At the protein level, p.(Gln575_Leu589dup) indicates the duplication of 15 amino acids (Gln 575 through Leu 589) in the JM domain of the KIT protein, starting with Gln at position 590 ([Fig. 3C](#f3-ijo-56-06-1468){ref-type="fig"}).

Discussion
==========

Genotype analysis of 70 patients from the Slovenian Cancer Registry was performed in the present study to determine the spectrum and frequency of *KIT* and *PDGFRA* alterations in Slovenian patients with metastatic GISTs, as well as the frequency of hot spot mutations in *KRAS, NRAS, BRAF, PIK3CA* and *AKT1* in *KIT/PDGFRA* WT GISTs. Known mutation status of the aforementioned genes has been proven to be an important prognostic and predictive factor in the management and treatment of patients with GIST with TKIs ([@b21-ijo-56-06-1468],[@b23-ijo-56-06-1468]).

Mutation analysis performed on Slovenian patients with GIST has confirmed a high degree of mutation heterogeneity in *KIT* and *PDGFRA* genes, as reported in previous studies ([@b24-ijo-56-06-1468]-[@b29-ijo-56-06-1468]). With direct Sanger sequencing of exons 9, 11, 13 and 17 of *KIT* gene and exons 12, 14 and 18 of *PDGFRA* gene, a total of 49 different alterations were detected. In the present study, the overall mutation rate was 88.5%, which was slightly higher than in a study from Italy (80%), yet comparable to frequencies observed in studies from Germany (86.1%) and Poland (85.1%), a French population-based study (*KIT*, 82.8%; *PDGFRA*, 2.1%), and in two phase III clinical trials that enrolled patients with metastatic GIST from the European Organisation for Research and Treatment of Cancer (*KIT*, 86.2%; *PDGFRA*, 1.6%) and Cancer and Leukemia Group B (*KIT*, 84.6%; *PDGFRA*, 2.65%) ([@b24-ijo-56-06-1468]-[@b29-ijo-56-06-1468]).

The mutation frequency in the patients analysed in the present study, was expectedly the highest in the *KIT* gene, with most mutations in exon 11 (86.7%). The highest mutation frequency in *KIT* exon 11 has also been reported in other studies (57, 66.1 and 87.3%, respectively) ([@b14-ijo-56-06-1468],[@b24-ijo-56-06-1468],[@b30-ijo-56-06-1468]). In 8 patients with GIST in the present study (11.4%), no alterations in *KIT/PDGFRA* genes were found. According to the literature, \~10-15% of adult GISTs are *KIT/PDGFRA* WT ([@b13-ijo-56-06-1468],[@b31-ijo-56-06-1468]). All 8 patients with no alterations in *KIT* or *PDGFRA* genes were also negative for hot spot mutations in *KRAS, NRAS, BRAF, PIK3CA* and *AKT1* genes, which are included in the RAS/RAF/MAPK and PI3K/AKT/mTOR signalling pathways, suggesting that the frequency of these mutations is low ([@b32-ijo-56-06-1468]). As reported by Shi *et al* ([@b33-ijo-56-06-1468]), patients with *KIT/PDGFRA* WT GIST can harbour mutations in *EGFR*. Since in the present cohort, only 8 patients had *KIT/PDGFRA* WT GIST, and since the likelihood of *EGFR* mutations in these patients is \<1%, the *EGFR* gene was not tested.

As aforementioned, the majority of identified *KIT* alterations in the present study were located in exon 11, between codons 550 and 580, which is similar to results from other studies ([@b2-ijo-56-06-1468],[@b10-ijo-56-06-1468],[@b34-ijo-56-06-1468]-[@b37-ijo-56-06-1468]). The most common type of *KIT* exon 11 alterations identified was an in-frame deletion of one to several codons. This is in line with the previously described frequencies of this change, representing 60-70% of all alterations in exon 11 ([@b30-ijo-56-06-1468],[@b38-ijo-56-06-1468],[@b39-ijo-56-06-1468]). Furthermore, it was observed that a high presence of deletions or deletion/insertions in the present study was detected between codons 556 and 561 (38.5%). Of these, a specific and commonly reported deletion, p.(Trp557_Lys558), was identified in 9.6%, which is the same as that reported by Emile *et al* ([@b27-ijo-56-06-1468]). Similar with the reports in the literature, the appearance of single nucleotide changes located around the same region of *KIT* exon 11, at codons 557, 559 and 560, such as p.(Trp557Arg), p.(Val559Asp) and p.(Val560Asp), was lower in the present study (5.8, 3.8 and 5.8%, respectively) ([@b27-ijo-56-06-1468],[@b40-ijo-56-06-1468]).

In the present cohort of patients with metastatic GIST, there was a relatively high frequency (11.5%) of specific *KIT* exon 9 duplication, p.(Ala502_Tyr503dup), which was reported to be more frequent in metastatic GISTs ([@b27-ijo-56-06-1468],[@b40-ijo-56-06-1468]).

In *KIT* exon 13, two single nucleotide changes, c.1924A\>G p.(Lys642Glu) and c.1961T\>C p.(Val654Ala), were identified. The substitution of amino acids Lys to Glu at codon 642, has been rarely described in literature and it has been suggested that this alteration disrupts normal auto-inhibitory function of the JM domain ([@b13-ijo-56-06-1468]).

Single nucleotide changes in *PDGFRA* were identified in exon 18, c.2525A\>T p.(Asp842Val), which is the most common *PDGFRA* mutation and accounts for 60-65% of all *PDGFRA* mutations seen in GIST (known to be resistant to the imatinib treatment) ([@b12-ijo-56-06-1468],[@b41-ijo-56-06-1468]). Notably, 1 patient was identified with a rare example of double mutant GIST, which had two different primary mutations in the *PDGFRA* gene, c.1936A\>G p.(Lys646Glu) and c.1975A\>C p.(Asn659His), both located in exon 14. These patient samples were collected prior to the initiation of TKI treatment. According to the literature, double mutant GISTs, harbouring two primary mutations in the *PDGFRA* gene, found prior to TKI therapy, are rare ([@b42-ijo-56-06-1468],[@b43-ijo-56-06-1468]).

Most of the patients who initially respond to imatinib develop resistance after a long period of treatment. Resistance to imatinib has been associated with secondary heterogeneous KIT receptor mutations in up to 90% of the patients. Secondary mutations most commonly arise in exons 13 and 14 (ATP-binding domain) or exons 17 and 18 (the activation loop), whereas primary KIT mutations predominantly affect the JM domain encoded by exon 11 ([@b44-ijo-56-06-1468]). The present study identified 6 patients with *KIT* exon 13 or 17 secondary mutation. Primary tumour samples from these patients were obtained after imatinib treatment, suggesting secondary mutations most probably occurred as a response to the treatment, which has been reported in previous studies ([@b10-ijo-56-06-1468],[@b41-ijo-56-06-1468],[@b45-ijo-56-06-1468]). In 3 out of 4 patients with secondary mutation in *KIT* exon 13 the same mutation was detected, a single nucleotide change c.1961T\>C p.(Val654Ala), confirming that this is the most commonly described secondary mutation ([@b10-ijo-56-06-1468]). Due to the existence of intra-tumour heterogeneity in GIST, with different clones being sensitive/resistant to different drugs, using a combination of different drugs could be a better approach for maximal clinical benefit ([@b44-ijo-56-06-1468]). The most relevant drug combination in GIST aims to circumvent upstream KIT reactivation following imatinib failure by blocking KIT-downstream effectors, or bypass oncoproteins or KIT-mutated receptors themselves. If two or more not cross-resistant TKIs are used simultaneously in patients with KIT-receptor dependant secondary mutations, their cumulative toxic side effects are very high. Therefore, for clinical use their simultaneous combination is hardly feasible. However, their rapid alternation could improve the modest clinical benefit seen when they are used sequentially as second or third line treatment ([@b44-ijo-56-06-1468]).

Eight novel likely pathogenic somatic variants were found in *KIT* exon 11 and they have been submitted to ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>), accession numbers SCV000902496 - SCV000902503. In order to characterize and classify the novel variants, the present study performed online *in silico* mutation prediction analysis using Align GVGD, MutationTaster2 and Cancer Genome Interpreter. Cancer Genome Interpreter categorises variants using OncodriveMUT bioinformatics method, which classifies variants into four classes: i) Predicted driver tier 1; ii) predicted driver tier 2 (where tier 1 and 2 represent higher and lower level of stringency of the driver prediction, respectively); iii) predicted passenger; and iv) polymorphism. Variants pathogenicity was determined according to ACMG/AMP guidelines using Genetic Variant Interpretation Tool (criterion selection PM1, PM2, PM4, PP3).

Exon 11 encodes the JM domain of KIT protein that prevents the kinase activation loop from shifting into the active state. Alterations in exon 11 predominantly disrupt the auto-inhibitory function and trigger ligand-independent receptor activation ([@b46-ijo-56-06-1468],[@b47-ijo-56-06-1468]). Since all eight novel variants detected in the present study were located in a well-established functional domain and mutational hot spot, ACMG/AMP criterion PM1 was applied. None of the novel variants are described in public databases of human variation GnomAD (<https://gnomad.broadinstitute.org/>) or ExAC (<https://www.re3data.org/repository/r3d100012122>), hence ACMG/AMP criterion PM2 was applied. All of the novel variants cause protein length change due to deletion, insertion or duplication, therefore ACMG/AMP criterion PM4 was applied.

Five of the novel variants in *KIT* gene detected in the present study were deletions or deletions/insertions, \[c.1652_1672del p.(Pro551_Lys558delinsGln), c.1653_1660delinsAA p.(Met552_Glu554delinsLys), c.1665_1672delinsCC p.(Trp557_Lys558del), c.1668_1686del p.(Trp557^\*^), and c.1676_1720del p.(Val559_Thr574delinsAla)\], localized within the most commonly mutated region of exon 11, between codons 550 and 580. Occurrence of deletions/insertions in this region of KIT receptor are described as activating alterations, which are according to literature, associated with malignant tumour behaviour ([@b2-ijo-56-06-1468],[@b8-ijo-56-06-1468],[@b48-ijo-56-06-1468],[@b49-ijo-56-06-1468]). Therefore it could be predicted that newly identified variants in the present study, \[c.1652_1672del p.(Pro551_Lys558delinsGln), c.1653_1660delinsAA p.(Met552_Glu554delinsLys), c.1676_1720del p.(Val559_Thr574delinsAla), and c.1665_1672delinsCC p.(Trp557_Lys558del)\], are a gain-of-function mutations, leading to protein activation. Variant c.1665_1672delinsCC p.(Trp557_Lys558del) results in deletion of two amino acids Trp557 and Lys558. Deletion of codons 557-558 is frequently reported in other studies and has been described to cause constitutive activation of *KIT* and increased ERK phosphorylation ([@b38-ijo-56-06-1468],[@b50-ijo-56-06-1468],[@b51-ijo-56-06-1468]). However, deletion of codons 557-558 as a result of this specific deletion of eight nucleotides from c.1665 to c.1672 coupled with insertion of two cytosines is firstly described in the present study. Deletion of codon 557 was detected also as a result of a novel deletion causing premature stop codon c.1668_1686del p.(Trp557^\*^). Because of the premature termination of the KIT protein at amino acid 557, it was predicted that p.(Trp557^\*^) leads to the loss of KIT protein function. Using Cancer Genome Interpreter, an evidence-based somatic variant classification tool, these five novel somatic variants were classified as predicted driver (tier 1 or tier 2), with high level of pathogenicity. Additionally, MutationTaster2 analysis predicted that four out of these five novel variants were disease-causing; based on their predicted oncogenic effect the ACMG/AMP criterion PP3 was applied.

Three of the novel variants were duplications of 17 to 45 nucleotides at the 3′-end of exon 11: c.1715_1756dup p.(Pro585_Arg586ins14), c.1721_1765dup p.(Arg588\_ Leu589ins15) and c.1722_1766dup p.(Gln575_Leu589dup). Duplications in GISTs are known to almost exclusively appear at the 3′-end of *KIT* exon 11, they range from 3 to 57 nucleotides and they are reported to have a relatively good clinical outcome ([@b52-ijo-56-06-1468],[@b53-ijo-56-06-1468]).

In conclusion, by identifying and classifying eight novel variants in *KIT* exon 11, and by detecting one double-mutant GIST with two mutations in *PDGFRA* exon 14, the present study contributes to broadening the spectrum of known mutations in GIST tumours. Mutation frequencies of *KIT* and *PDGFRA* gene observed in the present cohort (85.7 and 2.9%, respectively) are in accordance with previous literature. The current results also confirm the incidence of identified alterations in the previously reported and most frequently altered regions of *KIT* or *PDGFRA*, and suggest that the occurrence of alterations in other genes underlying GIST development, including *KRAS, NRAS, BRAF, PIK3CA* and *AKT1*, are very rare.

The present study is the first from Slovenia where a detailed characterization of gene abnormalities in patients with metastatic GIST from the Slovenian Cancer Registry has been performed. Knowing the accurate mutation status of patients with GIST is of great value for understanding GIST molecular biology, oncogenesis and GIST subtype classification, as well for the appropriate use of specific targeted therapy with *KIT/PDGFRA* TKIs.
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![Sanger sequencing electropherograms of double mutant gastrointestinal stromal tumour. (A) Forward sequence. Black arrow is indicating the nucleotide change c. 1936A\>G p.(Lys627Glu) in *PDGFRA* exon 14. Red arrow is indicating the nucleotide change c.1975A\>C p.(Asn659His) in *PDGFRA* exon 14. (B) Reverse sequence. Black arrow is indicating the nucleotide change c. 1936A\>G p.(Lys627Glu) in *PDGFRA* exon 14. Red arrow is indicating the nucleotide change c.1975A\>C p.(Asn659His) in *PDGFRA* exon 14.](IJO-56-06-1468-g00){#f1-ijo-56-06-1468}

![Sanger sequencing electropherograms of novel deletions or deletion/insertions. (A) Novel deletion c.1652_1672del p.(Pro551_Lys558delinsGln). (B) Novel deletion/insertion c.1653_1660delinsAA p.(Met552_Glu554delinsLys). (C) Novel deletion/insertion c.1665_1672delinsCC p.(Trp557_Lys558del). (D) Novel deletion c.1668_1686del p.(Trp557^\*^). (E) Novel deletion c.1676_1720del p.(Val559_Thr574delinsAla). Black arrows are indicating the start of deletions or deletion/insertions.](IJO-56-06-1468-g01){#f2-ijo-56-06-1468}

![Sanger sequencing electropherograms of novel duplications. (A) Novel duplication c.1715_1756dup p.(Pro585_Arg586ins14). (B) Novel duplication c.1721_1765dup p.(Arg588_Leu589ins15). (C) Novel duplication c.1722_1766dup p.(Gln575_Leu589dup). Black arrows are indicating the first duplicated nucleotide. Red arrows are indicating the last duplicated nucleotide.](IJO-56-06-1468-g02){#f3-ijo-56-06-1468}

###### 

Clinicopathological characteristics of 70 patients with gastrointestinal stromal tumour.

  Clinicopathological characteristic                                  n (%)
  ------------------------------------------------------------------- ------------
  Sex                                                                 
   Male                                                               32 (45.7)
   Female                                                             38 (54.3)
  Age                                                                 
   Median, years                                                      65
   Range, years                                                       34-89
   ≤60 years                                                          28 (40.0)
   \>60 years                                                         42 (60.0)
  Curative resection                                                  
   Yes                                                                13 (18.6)
   No                                                                 57 (81.4)
  Imatinib therapy                                                    
   Yes                                                                70 (100.0)
   No                                                                 0 (0.0)
  Outcome                                                             
   Alive                                                              21 (30.0)
   Dead                                                               49 (70.0)
  Primary tumour location                                             
   Oesophagus                                                         2 (2.9)
   Stomach                                                            33 (47.1)
   Small intestine                                                    25 (35.7)
   Rectum                                                             6 (8.6)
   Extraluminal                                                       4 (5.7)
  Mitotic index,/50 HPF                                               
   ≤5                                                                 22 (31.4)
   5.1-10                                                             11 (15.7)
   \>10                                                               37 (52.9)
  Primary tumour size, cm                                             
   0-5                                                                6 (8.5)
   5.1-10                                                             23 (32.9)
   \>10                                                               37 (52.9)
   Unknown                                                            4 (5.7)
  Risk classification[a](#tfn1-ijo-56-06-1468){ref-type="table-fn"}   
   High                                                               49 (70.0)
   Intermediate                                                       11 (15.7)
   Low                                                                9 (12.9)
   Very low                                                           1 (1.4)
  Morphology                                                          
   Spindle cells                                                      47 (67.1)
   Epithelioid cells                                                  8 (11.5)
   Mixed cells                                                        15 (21.4)

Risk groups for gastrointestinal tumours were adapted from Miettinen *et al* ([@b4-ijo-56-06-1468]).

###### 

Mutational status and mutation location of all 70 patients with GIST from the Slovenian Cancer Registry.

  Mutation genotype                                              Number of GISTs
  -------------------------------------------------------------- -------------------------------------------------
  *KIT/PDGFRA*-mutant GIST                                       62
  *KIT* (exon 9)                                                 6
  *KIT* (exon 11)                                                52
  *KIT* (exon 13)                                                5[a](#tfn2-ijo-56-06-1468){ref-type="table-fn"}
  *KIT* (exon 17)                                                3[b](#tfn3-ijo-56-06-1468){ref-type="table-fn"}
  *PDGFRA* (exon 12)                                             0
  *PDGFRA* (exon 14)                                             1[c](#tfn4-ijo-56-06-1468){ref-type="table-fn"}
  *PDGFRA* (exon 18)                                             1
  Wild-type[d](#tfn5-ijo-56-06-1468){ref-type="table-fn"} GIST   8

Two GISTs with primary mutation and three GISTs with secondary mutation.

Three GISTs with secondary mutation.

One GIST with two primary mutations.

Wild-type for *KIT, PDGFRA, BRAF, KRAS, NRAS, PIK3CA* and AKT1. GIST, gastrointestinal tumour.

###### 

Classification of eight novel heterozygous variants in *KIT* exon 11.

  Location of die alteration   In silico prediction         ACMG/AMP Classification by Genetic Variant Interpretation Tool   Cancer Genome Interpreter                                                                                                            
  ---------------------------- ---------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------- ------------------------ --------------------------
  c.l652_1672del               p.(Pro55 l_Lys558dehnsGln)   Class C65 (GV: 0.00 - GD: 75.14)                                 Prediction disease causing - long InDel. Model: complex_aae. prob: 0.999999999999935    PM1.PM2. PM4. PP3   Likely pathogenic (IV)   Predicted driver: tier 1
  c.l653_16bOdelinsAA          p.(Met552_Ghi554delinsLys)   Class C65 (GV: 0.00 - GD: 94.49)                                 Prediction disease causing. Model: complex_aae. prob: 0.895033008598755                 PM1.PM2. PM4. PP3   Likely pathogenic (IV)   Predicted driver: tier 1
  c.l665_1672delinsCC          p.(Trp557_Lys558del)         N/A                                                              Prediction polymorphism. Model: complex_aae. prob: 0.981440878256269                    PM1.PM2. PM4        Likely pathogenic (IV)   Predicted driver: tier 2
  c.l66S_16S6del               p.(Trp557\')                 N/A                                                              Prediction disease causing. Model: complex_aae. prob. 1                                 PM1.PM2. PM4. PP3   Likely pathogenic (IV)   Predicted driver: tier 2
  c.l676_1720del               p .(Val559_Thr574dehnsAla)   Class C55 (GV: 0.00 - GD: 64.43)                                 Prediction disease causing - long InDel. Model: complex_aae. prob: 0. 99999994804898S   PM1.PM2. PM4. PP3   Likely pathogenic (IV)   Predicted driver: tier 1
  c.l715_175odup               p.(Pro5S5_Arg5Soinsl4)       N/A                                                              Prediction polymorphism Model: complex_aae. prob: 0.999999947411599                     PM1.PM2. PM4        Likely pathogenic (IV)   Predicted passenger
  c,1721_1765dup               p.(Arg5S8_Leu5S9insl5)       N/A                                                              Prediction polymorphism. Model: complex_aae. prob: 0.999999998406041                    PM1.PM2. PM4        Likely pathogenic (IV)   Predicted passenger
  c,1722_1766dup               p .(Gln575_Leu5 89dup)       Class C65 (GV: 0.00 - GD: 112.44)                                Prediction polymorphism Model: complex_aae. prob: 0.999999998406041                     PM1.PM2. PM4        Likely pathogenic (IV)   Predicted driver: tier 2

Pathogenicity was determined using ACMG/AMP criterions. N/A, not avaliable.
